Pharmaceuticals News and Research

RSS

Live cell encapsulation technology helps overcome obstacles facing applications of live stem cell usage

Nuvilex, Inc. announced today testing confirmed that through use of live cell encapsulation technology, two major obstacles facing the vast and broad applications of live stem cell use have been overcome.

23 Nov 2011

New report: Sharp rise in number of energy drink-related ED visits from 2005-2009

A new nationwide report indicates that from 2005 to 2009, there has been a sharp increase in the number of emergency departments visits associated with the use of non-alcohol energy drinks - from 1,128 visits in 2005 to 13,114 visits in 2009.

23 Nov 2011

Accelr8 expands development plan for BACcel rapid diagnostic test

Accelr8 Technology Corporation announced that it successfully completed two technical feasibility studies for test methods that expand its BACcel rapid diagnostic test library and automation capabilities.

23 Nov 2011

New study: Exercise improves sleep quality

People sleep significantly better and feel more alert during the day if they get at least 150 minutes of exercise a week, a new study concludes.

23 Nov 2011

FDA accepts Regeneron's ARCALYST sBLA for review

Regeneron Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company's supplemental Biologics License Application (sBLA) for ARCALYST Injection for Subcutaneous Use for the prevention of gout flares in patients initiating uric acid-lowering therapy.

22 Nov 2011

Pfizer enters definitive agreement to acquire Excaliard

Pfizer Inc. and Excaliard Pharmaceuticals, Inc. announced today that they have entered into a definitive agreement under which Pfizer will acquire Excaliard, a privately owned biopharmaceutical company focused on developing novel drugs for the treatment of skin fibrosis, more commonly referred to as skin scarring. The acquisition is expected to close before the end of the year.

22 Nov 2011

Merck agrees to pay $950 million in Vioxx safety probe

Merck & Co. will pay $950 million and one of its units will plead guilty to a criminal charge to resolve a U.S. probe of its illegal marketing of the painkiller Vioxx.

22 Nov 2011

PAREXEL implements fMRI technology in early phase CNS drug development

PAREXEL International, a leading global biopharmaceutical services provider, today announced that it has enhanced its central nervous system (CNS) capabilities for clinical development through the implementation of functional magnetic resonance imaging (fMRI) technology in its Early Phase units.

From Parexel 22 Nov 2011

Decanoic acid can modulate glucose control

A Van Andel Research Institute (VARI) study published recently in the Journal of Biological Chemistry reveals that a natural fatty acid can serve as a regulator of blood sugar levels, which may have important applications in designing better and safer drugs for diabetes treatment.

22 Nov 2011

FDA accepts Otsuka's aripiprazole depot formulation NDA for review

Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S announced today that the U.S. Food and Drug Administration has determined that a new drug application (NDA) for Otsuka's investigational once-monthly aripiprazole depot formulation for the indication of maintenance treatment of schizophrenia in adults is sufficiently complete to permit a substantive review.

22 Nov 2011

MIT, Pfizer announce new location for CVMED and Neuroscience research units

Pfizer Inc. and the Massachusetts Institute of Technology (MIT) today held the official groundbreaking of the new location of Pfizer's Cardiovascular, Metabolic and Endocrine Diseases (CVMED) and Neuroscience research units at 610 Main Street, Cambridge, MA.

22 Nov 2011

Infarct size associated with time of day onset of ischemia

The size of a heart attack and subsequent left-ventricular function are significantly different based on the time of day onset of ischemia, according to a first of its kind study in humans, published online Nov. 17 in Circulation Research.

22 Nov 2011

'WHPA Prague Call to Action' fights against falsified medicines

In a first for the Central European region, national health professions organisations have discussed and endorsed the WHPA Prague Call to Action, to reduce the harmful impact of falsified medical products on patients and the public.

22 Nov 2011

Regeneron’s Eylea for treating age related macular degeneration gets FDA nod

Regeneron Pharmaceuticals has received marketing approval for their eye drug - Eylea, an injection meant to treat a common cause of blindness in older people. Eylea can be used to treat “wet” age-related macular degeneration. The only other drug approved for the condition is Lucentis from Roche, which was approved in 2006.

21 Nov 2011

Despite market constraints, the drug market for key hospital-treated infections will increase: Report

Decision Resources finds that the drug market for key hospital-treated infections that are of high interest to drug developers—most notably nosocomial pneumonia, bloodstream infections, skin and skin structure/surgical site infections and urinary tract infections—will increase from $3.3 billion in 2010 to just over $4 billion in 2020 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

21 Nov 2011

The Chinese acute coronary syndrome drug market to grow from $326M in 2010 to $448M in 2015

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the acute coronary syndrome (ACS) drug market in China will grow from $326 million in 2010 to $448 million in 2015.

21 Nov 2011

ChanRx to evaluate AFIB drug, vanoxerine with closed Series A funding

ChanRx is developing a superior drug for treatment of atrial fibrillation (AFIB), and has closed its Series A funding with investments from Sante Ventures and company founder, Dr. Arthur "Buzz" Brown. The company, a spin out of Cleveland-based ChanTest, will use the funding to further evaluate the safety and efficacy of its proprietary AFIB drug, vanoxerine.

21 Nov 2011